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ABSTRACT  36 
 37 
Poly(amidoamine)s (PAAs) are multifunctional tert-amine polymers endowed with high structural 38 
versatility. Here we report on the screening of a minilibrary of PAAs against a panel of viruses. The 39 
PAA AGMA1 showed antiviral activity against herpes simplex virus, human cytomegalovirus, 40 
human papillomavirus-16, and respiratory syncytial virus, but not against human rotavirus and 41 
vesicular stomatitis virus. The results suggest the contribution of both polycationic nature and side 42 
guanidine groups in imparting antiviral activity. 43 
44 
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 The development of antiviral molecules usually focuses on either preventing virus entry into the 45 
host cell or inhibiting virus replication following host infection. The first strategy may be based on 46 
antiviral polyanionic polymers capable of competitively blocking the interaction between viral 47 
proteins and cell surface heparan sulfate proteoglycans (HSPGs), which are exploited as attachment 48 
receptors by many viruses (1, 2, 3, 4). Notwithstanding the large number of studies demonstrating 49 
their efficacy in preclinical models, polyanionic polymers somehow failed in clinical trials (5). 50 
Unlike polyanions, polycationic polymers have been less investigated as antiviral compounds. In 51 
principle, polycations could act as antivirals by electrostatically interacting either with the 52 
negatively charged cell membrane or with the envelope of lipid-enveloped viruses, thus preventing 53 
virus adsorption onto cell surfaces, or directly inactivating the virus particle. In this context, it was 54 
shown that the cationic poly(acrylic ester) Eudragit E100, endowed with a membrane-destabilizing 55 
activity, exerts antiviral activity against a panel of lipid-enveloped viruses (6, 7). Another study 56 
demonstrated that polyethylenimine, a cationic polymer able to condense DNA and mediate gene 57 
transfer into mammalian cells, inhibits infection by human cytomegalovirus (HCMV) and human 58 
papillomavirus (HPV), a lipid-enveloped virus and a non-enveloped virus respectively (8). 59 
Poly(amidoamine)s (PAAs) are multifunctional tert-amine polymers endowed with high structural 60 
versatility, obtained by Michael polyaddition of amines and bis-acrylamides (9). The repeating units 61 
of PAAs can be designed to be reminiscent of peptides. For instance, an amphoteric, prevailingly 62 
cationic PAA named AGMA1 is a polymer mimic of arg-gly-glu peptide (RGD) (10, 11).  63 
In the search of new antiviral compounds, a minilibrary of PAAs was screened against a panel of 64 
seven viruses, namely herpes simplex virus type 1 and 2 (HSV-1, HSV-2), HCMV, HPV-16, 65 
human respiratory syncytial virus (RSV), human rotavirus (HRV) and vesicular stomatitis virus 66 
(VSV) chosen as representatives of different virus characteristics such as presence or absence of 67 
lipid envelope, nature of genome (DNA or RNA) and HSPG dependency for virus attachment (12, 68 
13, 14, 15, 16). 69 
The minilibrary included three water-soluble PAAs, ISA1, ISA23 and AGMA1, whose structures 70 
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are reported in Figure 1. The copolymeric ISA1 (17), containing two randomly distributed repeating 71 
units present in equal amounts, and the homopolymeric ISA 23 (17, 18) and AGMA1 (19) were 72 
prepared as previously reported. AGMA1 fractions with different average molecular weights were 73 
obtained by ultrafiltration against water using membranes with different nominal molecular weight 74 
cut off, as previously described (20). ISA1, is weakly cationic, but ISA23 and AGMA1 are 75 
amphoteric, with isoelectric points ~5.2 and ~10.3. As reported in Table 1, at pH 7.4, these PAAs 76 
have, respectively, +0.55, -0.55 and +0.55 average charges per unit. For ISA1, the reported value 77 
corresponds to the ionization degree of its ter-amine groups, no other ionizable groups being 78 
present. For ISA23 and AGMA1, the reported figures correspond to the excess negative over 79 
positive charges and vice-versa, that is, respectively, -1+0.45 and -1+1.55 per unit. Thus, at pH 7.4 80 
the overall cationic charge of ISA1 and AGMA1 is superficially similar, but a deeper insight 81 
reveals that their real charge distribution is different.  82 
Antiviral assays were performed by infecting cell monolayers in presence of serial dilutions of 83 
compounds for 2 hours at 37°C to generate dose-response curves and a selectivity profile of the 84 
PAAs antiviral spectrum. The inocula were subsequently washed out and replaced with culture 85 
medium containing the same concentration of compounds. The effect on HSV and VSV infections 86 
was evaluated by a standard plaque reduction assay on pre-seeded Vero cells in 24-well plates (10 x 87 
10
4
 cells) infecting with 300 pfu/well of clinical isolates of HSV-1 and HSV-2 (21), and Vesicular 88 
stomatitis virus (VSV) serotype Indiana; after incubation for 24 hours (HSV-2 and VSV) or 48 89 
hours (HSV-1) at 37°C in 5% CO2, cells were fixed and stained with 0.1% crystal violet in 20% 90 
ethanol and viral plaques were counted. The mean plaque count for each drug concentration was 91 
expressed as a percentage of the mean plaque count of the control.   92 
In HCMV and RSV inhibition assays, infected cells were fixed and subjected to virus-specific 93 
immunostaining as described previously (22, 23). In these assays, cells were pre-seeded at a density 94 
of 6 x 10
3
/well in 96-well plates. Hep-2 cells were infected with RSV strain A2 (60 pfu/well) 95 
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whereas HELF cells with HCMV strain AD169 (24 pfu/well). Three days (RSV) or five days 96 
(HCMV) post-infection viral immunostained plaques were microscopically counted. 97 
HPV inhibition assays were performed on preplated 293TT cells (2 x 10
4
/well in 96-well plates) 98 
using HPV-16 SEAP (secreted alkaline phosphatase) pseudoviruses (PsV) at the final concentration 99 
of 1 ng/ml L1; three days post infection the SEAP content in the clarified supernatant was 100 
determined as previously described (24). Plasmids used for PsV production were kindly provided 101 
by J. Schiller (NCI, Bethesda USA). Antiviral assays for rotavirus were carried out on preplated 102 
MA104 cells (1 x 10
4
/well in 96-well plates) using human rotavirus strain Wa (200 pfu/well). After 103 
16 hours, viral foci were determined by indirect immunostaining (24). 104 
The end-points of the assays were the effective compound concentration that reduced the viral 105 
plaque/focus formation or SEAP activity by 50% (EC50) in comparison to the untreated control. F 106 
test was used to compare LogEC50s  and  two-way analysis of variance to analyze the significance 107 
between percentages of infection at the same doses of different compounds not able to generate 108 
EC50s. Values of p < 0.05 were considered statistically significant. The EC50 values and all 109 
statistical analyses were calculated by using the program PRISM 4 (GraphPad Software, San Diego, 110 
California, U.S.A.). Cell viability assays were performed on cells pre-seeded in 96-well plates 111 
under identical culture conditions of antiviral assays (i.e. cell density and  time of incubation with 112 
compounds) using CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA). The 50% 113 
cytotoxic concentrations (CC50) were determined using Prism software and the selectivity index 114 
(SI) was calculated by dividing the CC50 by the EC50 (21).  All data were generated from duplicate 115 
wells in at least three independent experiments. Heparin was included in the study as a positive 116 
control being a known inhibitor of HSPG-dependent viruses (e.g. HSV-1, HSV-2, HCMV, RSV 117 
and HPV-16) (25, 26, 27, 28). As expected, heparin blocked infection by HSPG-dependent viruses 118 
but not that by VSV and HRV which are not dependent on HSPG (Table 2). 119 
Data reported in Table 2 prompt the following observations. The PAA antiviral effect was not a 120 
consequence of cytotoxicity, since none of the screened compounds significantly reduced cell 121 
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viability at any concentration tested (i.e. up to 300 g/ml); therefore their CC50 values may be 122 
considered to be higher than 300 μg/mL in all the cell lines tested.  123 
Polydisperse AGMA1 strongly inhibited infections by HSV-1, HSV-2, HCMV and HPV-16, 124 
generating dose response-curves with EC50 values of 3.04, 5.34, 0.76, 0.54 μg/mL respectively. 125 
Interestingly, AGMA1 was significantly more active than heparin against HSV-1 and HPV-16 126 
infections, whereas was as active as heparin against HCMV infection (p < 0.05). By contrast, 127 
polydisperse AGMA1 was inactive against RSV, HRV and VSV.  128 
To evaluate the influence of molecular weight on antiviral potency, three additional linear AGMA1 129 
fractions were prepared, namely AGMA14 (M n  4500), AGMA17 (M n  7800) and AGMA120 (M n  130 
20500) (Table 1). As depicted in Table 2, fractions with lower and higher molecular weights than 131 
polydisperse AGMA1 (M n  10100) maintained inhibitory activity against HSV-1, HSV-2, HCMV 132 
and HPV-16 although to different extents. AGMA14 showed a stronger anti-HSV-1 activity than 133 
that of heparin and all fractions were more active than heparin against HPV-16 infection (p < 0.05). 134 
No statistically significant differences were observed between EC50 of heparin and EC50s of 135 
AGMA14 against HSV-2 and HCMV infections and between EC50 of heparin and EC50 of 136 
AGMA120  against HSV-1 infection. 137 
Unlike polydisperse AGMA1, AGMA14, AGMA17 and AGMA120 were active also against RSV 138 
with EC50 values of 8.87, 7.44, and 1.37 μg/mL respectively. Both polydisperse AGMA1 and 139 
AGMA1 fractions failed to display any significant inhibitory effect against HRV and VSV.  The 140 
antiviral activity of AGMA1 seems not to be dependent on its molecular weight for HSV-1, HSV-2, 141 
HCMV and HPV-16, instead there is a clear relationship between AGMA1 fractions’ size and anti-142 
RSV potency. Explaining why polydisperse AGMA1 did not exert a detectable anti-RSV activity, 143 
while all of the size fractions did, demands further investigation. 144 
Polymers do not consist of a single molecular specie, but rather of families of homologous species 145 
differing for the number of repeating units. Therefore, it is considered inappropriate to adopt the 146 
molar concept describing their properties. Nevertheless, to compare activity across compounds, 147 
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Table 3 shows the EC50 values of AGMA1 fractions and heparin expressed in terms of molarity 148 
instead of g/ml, considering the average molecular weight reported in Table 1. It was not possible 149 
to convert the average molecular mass of polydisperse AGMA1 in terms of molar equivalents since 150 
its molecular mass is not univocally defined. Interestingly, the relationship between AGMA1 151 
fractions’ size and anti-RSV potency, reported in text when data were expressed in terms of g/ml, 152 
is preserved. Furthermore, AGMA17 and AGMA120 preserved a higher anti-HPV-16 activity than 153 
that of heparin (p < 0.05). By contrast, the antiviral activity of AGMA14 in terms of molarity is 154 
lower than that in terms of g/ml: its activity is similar to that of heparin against HSV-1 and HPV-155 
16 infections and is lower to that of heparin against HSV-2 and HCMV (p < 0.05). This behavior 156 
might be ascribed to a more rigidity of the polymer with the lowest molecular weight. Being all the 157 
polymers polyelectrolytes, it is necessary to take into account that the charge density markedly 158 
affect the dynamic rheological properties, the flexibility and the chain entanglements. Increased 159 
polymer charge density results in intermolecular electrostatic repulsion and increased polymer 160 
solubility. 161 
Next, to investigate whether the activity of AGMA1 was specifically due to the structure of its 162 
repeating unit, the antiviral activity of ISA1 and ISA23 was assessed. Overall, whilst AGMA1 was 163 
active against HSV-1, HSV-2, HCMV, RSV and HPV-16 infection, ISA1 was active only against 164 
HCMV and RSV with a lower activity than that of heparin and was as active as heparin against 165 
HPV-16 (p < 0.05). ISA23 was inactive in all cases. At pH 7.4, both AGMA1 and ISA1 are 166 
positively charged, whereas ISA23 is negatively charged. It is known that polycationic polymers 167 
establish ionic interactions with the cell surface HSPG (29, 30), a feature that may impart antiviral 168 
activity to these compounds. This feature, along with the finding that the active PAAs have the 169 
same antiviral activity spectrum as heparin, supports the hypothesis that PAAs may exert their 170 
antiviral action, at least in part, by interacting with HSPG thus preventing virus attachment. 171 
However, notwithstanding AGMA1 and ISA1 carry the same density of positive charges, i.e. + 172 
0.55, AGMA1 showed a greater activity for HSV-1, HSV-2 and HPV-16. This could be due to the 173 
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different real charge distribution on the macromolecules and to its side guanidine groups reinforcing 174 
membrane interactions, according to their well-known chaotropic properties (31). By contrast, the 175 
guanidine side group does not seem to be necessary for the anti-HCMV activity. Furthermore, a 176 
different chain entanglement might explain the different activity of AGMA1 in respect to RSV. 177 
Overall these results provide a starting point to tailor a macromolecule with enhanced antiviral 178 
activity  against  a selected virus. Future work will be focused on narrowing the molecular mass 179 
distribution of PAA samples to assist in preclinical development. 180 
Studies are ongoing to elucidate the mechanism of action the active PAAs and their antiviral 181 
potential and biocompatibility profile in preclinical models. 182 
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FIGURE LEGENDS 289 
Figure 1. Chemical structure of AGMA1, ISA1 and ISA 23  repeating units  290 
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Figure 1. Chemical structure of AGMA1, ISA1 and ISA 23  repeating units  
ISA1 
ISA23 
AGMA1 
Table 1. Physico-chemical characteristics of PAAs  
Polymer M n  Net average charge 
per unit at pH 7.4 
Average negative charges 
per unit at pH 7.4 
Average positive charges 
per unit at pH 7.4 
Polydisperse 
AGMA1 
AGMA14 
 
10100 
4500 
+ 0.55 
+ 0.55 
-1.00 
-1.00 
+ 1.55 
+ 1.55 
AGMA17 
 
7800 + 0.55 -1.00 + 1.55 
AGMA120 
 
20500 + 0.55 -1.00 + 1.55 
ISA1 
 
13600 + 0.55 0.0 + 0.55 
ISA23 16500 - 0.55 -1.00 + 0.45 
 
M n  = number average molecular weight. n
i
i
n
i
ii
n
N
MN
M
1
1
, where iN number of macromolecules 
containing i repeating units, and iM  weight of macromolecules containing i repeating units. 
Table 2. Antiviral activities of PAAs and heparin 
Compounds virus EC50 (g/ml)
a 
(95% C.I.)
b 
CC50 (g/ml)
c SI 
AGMA1 HSV-1 3.04 (1.75 - 5.28) > 300 > 98.7 
 HSV-2 5.34 (1.85 - 15.4) > 300 > 56.2 
 HCMV 0.76 (0.40 -1.47) > 300 > 395 
 HPV-16 0.54 (0.53 - 0.55) > 300 > 556 
 RSV > 100 > 300 n.a.
d
 
 HRV > 100 > 300 n.a. 
 VSV > 100 > 300 n.a. 
AGMA14 HSV-1 1.93 (1.43 - 2.61) > 300 > 155 
 HSV-2 1.35 (0.57 - 3.17) > 300 > 222 
 HCMV 0.39 (0.11 - 1.30) > 300 > 769 
 HPV-16 0.92 (0.53 - 1.58) > 300 > 326 
 RSV 8.87 (6.51 - 12.1) > 300 > 33.8 
 HRV 
VSV 
> 100 
> 100 
> 300 
> 300 
n.a. 
n.a. 
AGMA17 HSV-1 17.0 (11.4 - 25.4) > 300 > 17.6 
 HSV-2 4.80 (3.13 - 7.35) > 300 > 62.5 
 HCMV 4.45 (3.28 - 5.90) > 300 > 67.4 
 HPV-16 0.79 (0.44 - 1.44) > 300 > 380 
 RSV 7.44 (3.11 - 17.8) > 300 > 40.3 
 HRV > 100 > 300 n.a. 
 VSV > 100 > 300 n.a. 
AGMA120 HSV-1 5.10 (3.21 - 8.10) > 300 > 58.8 
 HSV-2 
HCMV 
2.82 (1.72 - 4.64) 
4.14 (2.50 - 6.86) 
> 300 
> 300 
> 106 
> 72.5 
 HPV-16 0.72 (0.50 - 1.06) > 300 > 417 
 RSV 1.37 (1.11 - 1.68) > 300 > 219 
 HRV > 100 > 300 n.a. 
 VSV > 100 > 300 n.a. 
ISA1 HSV-1 > 100 > 300 n.a. 
 HSV-2 > 100 > 300 n.a. 
 HCMV 1.26 (0.79 - 2.00) > 300 > 238 
 HPV-16 3.55 (1.97 - 6.40) > 300 > 84.5 
 RSV 9.54 (5.51 - 16.5) > 300 > 31.4 
 HRV > 100 > 300 n.a. 
 VSV > 100 > 300 n.a. 
ISA23 HSV-1 > 100 > 300 n.a. 
 HSV-2 > 100 > 300 n.a. 
 HCMV > 100 > 300 n.a. 
 HPV-16 > 100 > 300 n.a. 
 RSV > 100 > 300 n.a. 
 HRV > 100 > 300 n.a. 
 
Heparin 
 
 
 
VSV 
HSV-1 
HSV-2 
HCMV 
HPV-16 
> 100 
5.22 (4.22 - 6.45) 
0.67 (0.39 - 1.18) 
0.38 (0.24 - 0.64) 
2.88 (1.81 - 4.57) 
> 300 
> 300 
> 300 
> 300 
> 300 
n.a. 
> 57.5 
> 448 
> 789 
> 104 
RSV 
HRV 
VSV 
0.05 (0.04 – 0.06) 
> 100 
> 100 
> 300 
> 300 
> 300 
> 6000 
n.a. 
n.a. 
a
 EC50: 50% effective concentration  
b
 95% CI: 95% confidence interval 
c 
CC50: 50% cytotoxic concentration  
d
 n.a.: not assessable 
Table 3. Antiviral activities of Poly(amidoamine)s expressed in terms of approximate molar values 
Compounds virus EC50 (M)
a
 
(95% C.I.)
b 
CC50 (M)
c
 
AGMA14 HSV-1 0.43 (0.30 – 0.61) > 66.67 
 HSV-2 0.30 (0.11 – 0.80) > 66.67 
 HCMV 0.33 (0.09 – 1.27) > 66.67 
 HPV-16 0.20 (0.12 – 0.33) > 66.67 
 RSV 1.97 (1.44 – 2.69) > 66.67 
 HRV 
VSV 
> 22.22 
> 22.22 
> 66.67 
> 66.67 
AGMA17 HSV-1 2.18 (0.65 – 7.33) > 38.46  
 HSV-2 0.61 (0.38 – 1.00) > 38.46  
 HCMV 0.56 (0.41 – 0.76) > 38.46 
 HPV-16 0.10 (0.06 – 0.18) > 38.46 
 RSV 0.95 (0.40 – 2.28) > 38.46 
 HRV > 12.82 > 38.46 
 VSV > 12.82 > 38.46 
AGMA120 HSV-1 0.25 (0.16 – 0.40) > 14.63 
 HSV-2 
HCMV 
0.14 (0.08 – 0.23) 
0.20 (0.12 – 0.33) 
> 14.63 
> 14.63 
 HPV-16 0.04 (0.02 – 0.51) > 14.63 
 RSV 0.07 (0.05 – 0.08) > 14.63 
 HRV > 4.87 > 14.63 
 VSV > 4.87 > 14.63 
Heparin HSV-1 
HSV-2 
HCMV 
HPV-16 
RSV 
HRV 
0.38 (0.30 – 0.49) 
0.04 (0.03 – 0.07) 
0.03 (0.02 – 0.05) 
0.21 (0.13 – 0.36) 
0.01 (0.00 – 0.01) 
> 7.30 
> 21.90 
> 21.90 
> 21.90 
> 21.90 
> 21.90 
> 21.90 
a
 EC50: 50% effective concentration  
b
 95% CI: 95% confidence interval 
c 
CC50: 50% cytotoxic concentration  
 
